Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Valvular heart disease with the use of fenfluramine-phentermine.

Surapaneni P, Vinales KL, Najib MQ, Chaliki HP.

Tex Heart Inst J. 2011;38(5):581-3.

2.

Valvular heart disease associated with fenfluramine-phentermine.

Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV.

N Engl J Med. 1997 Aug 28;337(9):581-8. Erratum in: N Engl J Med 1997 Dec 11;337(24):1783.

3.

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.

Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL.

JAMA. 2000 Apr 5;283(13):1703-9.

PMID:
10755496
4.

The longitudinal effects of fenfluramine-phentermine use.

Fleming RM, Boyd LB.

Angiology. 2007 Jun-Jul;58(3):353-9.

PMID:
17626991
5.

Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.

Gardin JM, Weissman NJ, Leung C, Panza JA, Fernicola D, Davis KD, Constantine GD, Reid CL.

JAMA. 2001 Oct 24-31;286(16):2011-4.

PMID:
11667938
6.

Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.

Kancherla MK, Salti HI, Mulderink TA, Parker M, Bonow RO, Mehlman DJ.

Am J Cardiol. 1999 Dec 1;84(11):1335-8.

PMID:
10614800
7.

[Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants].

Goldstein SE, Levy Y, Shoenfeld Y.

Harefuah. 1998 Dec 1;135(11):489-92, 568. Hebrew.

PMID:
10911459
8.

Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.

Hensrud DD, Connolly HM, Grogan M, Miller FA, Bailey KR, Jensen MD.

Mayo Clin Proc. 1999 Dec;74(12):1191-7.

PMID:
10593346
9.

Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study.

Maréchaux S, Jeu A, Jobic Y, Ederhy S, Donal E, Réant P, Abouth S, Arnasteen E, Boulanger J, Ennezat PV, Garban T, Szymanski C, Tribouilloy C.

Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):349-56. doi: 10.1016/j.acvd.2013.04.006. Epub 2013 May 31.

10.

Anorectic therapy and valvular heart disease: a reappraisal.

Silvestry FE, St John Sutton M.

Eur Heart J. 1999 Jul;20(13):917-20. No abstract available.

PMID:
10361039
11.

Further cases of valvular heart disease associated with fenfluramine-phentermine.

Graham DJ, Green L.

N Engl J Med. 1997 Aug 28;337(9):635. No abstract available.

12.

Severe heart valve disease on appetite suppressants.

[No authors listed]

Prescrire Int. 1998 Feb;7(33):19-20. No abstract available.

PMID:
10183395
13.

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.

Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT.

N Engl J Med. 1998 Sep 10;339(11):713-8.

14.

Operation for anorexigen-associated valvular heart disease.

Caccitolo JA, Connolly HM, Rubenson DS, Orszulak TA, Schaff HV.

J Thorac Cardiovasc Surg. 2001 Oct;122(4):656-64.

15.

Valvular heart disease in fenfluramine- phentermine-treated patients: a comparison with control patients.

Wadden TA, Silvestry FE, Aber JL, Berkowitz RI, Foster GD, Sutton MG.

Obes Res. 1999 May;7(3):309-10. No abstract available.

16.

Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment.

Cannistra LB, Cannistra AJ.

N Engl J Med. 1998 Sep 10;339(11):771. No abstract available.

17.

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.

Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE.

N Engl J Med. 1998 Sep 10;339(11):719-24.

18.

Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.

Teramae CY, Connolly HM, Grogan M, Miller FA Jr.

Mayo Clin Proc. 2000 May;75(5):456-61.

PMID:
10807073
19.

Valvular heart disease associated with fenfluramine-phentermine.

Spitzer WO.

N Engl J Med. 1997 Dec 11;337(24):1774-5; author reply 1775-6. No abstract available.

PMID:
9411251
20.

[Valvular heart disease and primary pulmonary hypertension associated with fenfluramine-phentermine].

Wolf I, Mouallem M, Farfel Z.

Harefuah. 1998 Dec 1;135(11):515-7. Review. Hebrew. No abstract available.

PMID:
10911468

Supplemental Content

Support Center